These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 31432184)
1. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184 [TBL] [Abstract][Full Text] [Related]
3. MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells. Shiratori E; Itoh M; Tohda S Anticancer Res; 2017 Nov; 37(11):6203-6209. PubMed ID: 29061802 [TBL] [Abstract][Full Text] [Related]
4. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. Loiarro M; Capolunghi F; Fantò N; Gallo G; Campo S; Arseni B; Carsetti R; Carminati P; De Santis R; Ruggiero V; Sette C J Leukoc Biol; 2007 Oct; 82(4):801-10. PubMed ID: 17548806 [TBL] [Abstract][Full Text] [Related]
5. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863 [TBL] [Abstract][Full Text] [Related]
6. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Choi JW; Kim Y; Lee JH; Kim YS Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077 [TBL] [Abstract][Full Text] [Related]
7. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841 [No Abstract] [Full Text] [Related]
8. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955 [TBL] [Abstract][Full Text] [Related]
9. Downregulation of Inflammatory Cytokine Release from IL-1β and LPS-Stimulated PBMC Orchestrated by ST2825, a MyD88 Dimerisation Inhibitor. Ramírez-Pérez S; Hernández-Palma LA; Oregon-Romero E; Anaya-Macías BU; García-Arellano S; González-Estevez G; Muñoz-Valle JF Molecules; 2020 Sep; 25(18):. PubMed ID: 32967164 [TBL] [Abstract][Full Text] [Related]
10. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451 [TBL] [Abstract][Full Text] [Related]
11. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557 [TBL] [Abstract][Full Text] [Related]
12. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211 [TBL] [Abstract][Full Text] [Related]
13. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma. Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783 [TBL] [Abstract][Full Text] [Related]
14. The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer. Lu S; He T; Zhang Y; Zhou B; Zhang Q; Yan S Oncol Rep; 2023 Aug; 50(2):. PubMed ID: 37326109 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679 [TBL] [Abstract][Full Text] [Related]
16. Effect of ST2825 on the proliferation and apoptosis of human hepatocellular carcinoma cells. Deng Y; Sun J; Zhang LD Genet Mol Res; 2016 Mar; 15(1):15016826. PubMed ID: 26985932 [TBL] [Abstract][Full Text] [Related]
17. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547 [TBL] [Abstract][Full Text] [Related]
18. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling. Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699 [TBL] [Abstract][Full Text] [Related]
19. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251 [TBL] [Abstract][Full Text] [Related]
20. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]